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SHP2 promotes Triple Negative Breast Cancer by mediating crosstalk between EGFR and 
Wnt/β-catenin signaling pathways 
Elisha Martin  
 Basel-like/ Triple Negative Breast Cancer (BTBC) are a subtype of Breast Cancer that are clinically 
characterized as an aggressive and highly metastatic disease phenotype  and poor outcome for women 
who are diagnosed with this disease.  Patients with BTBCs lack treatment options for target 
therapeutics that are available for other Breast Cancer subtypes (e.g. tamoxifen and herceptin) and 
have been shown to have a disproportional mortality rate in minority and in young woman of all races. 
The need to find and characterize a potential therapeutic target for BTBC is an exterimal important 
focus for many researcher laboratories.  Src-homology phosphotyrosyl phosphatase 2 (SHP2) could 
potentially be therapeutic target for BTBC, for the reason it’s an essential mediator of Receptor  
Tyrosine Kinases (RTKs),which are dysregulated in BTBC such as Epidermal Growth Factor 
Receptor (EGFR), c-Met, Fibroblast Growth Factor Receptor (FGFR) and ect. Here, we show that 
silencing of SHP2 in BTBC leads to a reduction in cell proliferation, transformation and a loss of a 
cancer stem cells phenotype.  Furthermore, silencing of SHP2 in BTBC leads to a loss of basal and 
ligand stimulation signaling downstream to PI3k/AKT and MAPK/ERK1/2 pathways form RTK 
and RTK expression. We also show that silencing of SHP2 causes a reduction in β-catenin proteins, 
loss of  β-catenin target gene expression and  loss of nuclear localization. Silencing of β-catenin in 
BTBC also showed a reduction in cell proliferation, transformation, loss of EGFR protein and 
mRNA expression along with a reduction in SHP2 protein levels. Taken together, these 
observations suggest that SHP2 is essential for RTK signaling, expression and β -catenin proteins 
stability which is need for expression of RTKs in BTBC, showing that SHP2 can be a  potential 
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A. Literature Review 
A1. Epidemiology  
Breast cancer (BC) is the second leading cause of death for women worldwide. BC also affects 
men, but at a relatively very low rate. In 2012 alone, there were an estimated 1.7 million new cases 
and 522,000 deaths of BC. When it comes to the United States, the incidence is even higher with an 
estimated 234,190 new cases and 40,730 deaths in 2015 alone. Multiple factors are known to be risk 
factors for BC development. These include, environment, life style, racial differences, age, age of 
giving the first birth, number of births, age of menarche and menopause, diet, alcohol and tobacco use, 
hormone replacement therapies, family history, and obesity.  
Developed countries have a higher trend for breast cancer incidence. One suggested reason for 
this has been difference in life style of women in developed versus developing countries. For instance, 
frequent consumption of processed food, which is heavily used in developed countries, is known to 
increase BC and other cancer risks both in women and men [1]  Other reasons for this difference are 
suggested to be industrial toxins and environmental prolusion [2, 3] .  
Women of different racial and economical backgrounds are affected differentially by BC in 
terms of percentage of women diagnosed, survival rate and treatment options. For instance, the 
incidence rate of BC in the United States is higher among White non-hispanic women with 127.6 per 
100,000 followed by African American women with 123 per 100, 000. This rate is much lower in 
Asian American and Pacific Islander women with 86 per 100,000 [4] .  However, African American 
women have the highest mortality rate compared to other ethnic groups in the United States with a 
mortality rate of 31.4 per 100,000, followed by White non-Hispanic women with 22.2 per 100,000. 
One reason for this disproportionality in mortality versus incidence rate is difference in economical 
standing [5, 6] . The prevailing poverty and lack of insurance leaves some African American women 
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unable to seek proper treatment. There is also information about some doctors withholding 
information on available therapeutic options because of an individual’s inability to pay for treatment 
[7]. Cultural differences that affect life style particularly diet and alcohol and tobacco use are also 
known to contribute to differences in BC incidence rate.  
Women who give birth before the age of 30 have a lower chance of getting BC than those who 
give birth after 30.  Furthermore, women with pregnancies have a lower chance of developing BC.  
Women who start menstruating before age 12 have a higher risk of BC when compared to those who 
start at a later age.  With regard to menopausal state, women who lag have a higher risk of BC those 
who start before age 55[5] . Alcohol use has been shown to increases the risk of a woman to develop 
BC compared to non-alcohol drinkers.  Women who drink alcohol have higher levels of estrogen in 
their blood than those who don’t drink.  Smoking is a risk factor that is still under study with data 
supporting and disclaiming smoking as a risk for BC [8, 9]. 
Obesity has also been shown to be associated with BC risk.  Studies have shown that obesity 
after menopause leads to increased risk of BC. It is suggested that increased fat tissue in the body leads 
to increased production of estrogen by adipocytes, leading to increased estrogen signaling that 
activates proliferation of breast cells [10] .  Hormone replacement therapies have been used to relieve 
symptoms of menopause and to stop osteoporosis.  However, reports indicate that such treatments may 
increase BC risk due to increased estrogen signaling [11] . This is a possibility since increased 
estrogen signaling is the cause of hormone-positive breast cancer [12] . Obesity also leads to an 
increased blood insulin level, which can induce growth of breast cells and cancer development[9] .  
Family history of BC also is considered a risk factor particularly if the patient carries genetically 
transmissible mutations such as deletion or functional inactivation of the breast cancer susceptibility 






A2.  Physiology of the breast 
The physiological role of the breast is milk production as a nutrient for new born babies. 
During pregnancy, the breast epithelia goes through several rounds of cellular proliferation and 
differentiation that lead to formation of lobuloalvelar structures and ducts that are connected to the 
nipple. A fully developed breast is composed of multiple lobes formed by 20 to 40 lobules and 
ducts that emanate from them. The lobules within each lobe are connected to ducts and collection 
ducts that lead to the nipple of each breast. These epithelial structures are spread throughout the 
fatty and fibrous connective tissues that form most of the mass of the breast.  The lobes and 
collection ducts connected the nipple resemble bunches of grapes connected to the stalk of the grape 
tree. During lactation, milk is produced in the lobules and then carried by the ducts to collection 
ducts and finally to the nipples. The nipple is surrounded externally by a glandular tissue called 
areola composed of sweet glands that lubricate the nipple during breast feeding.  Inside the breast 
there are lymph nodes from the lymphatic system located in fatty and fibrous connective tissues 
along with blood vessels 
 
A3. Breast cancer  
A3.1 Classification 
BC is broadly classified into three major categories based on state of estrogen receptor (ER), 
progesterone receptor (PR) and epidermal growth factor receptor 2 (EGFR2), also known as human 
EGFR2 (HER2), expression. Immunohistochemistry (IHC) is the primary method to classify BC as 
hormone positive (ER/PR-positive), HER2-positive and triple-negative (negative for ER, PR and 
HER2 expression).  The hormone-positive subtype is identified by expression of the estrogen and 
progesterone receptors (ER and PR), while the HER2-positive subtype by HER2 overexpression. The 
subtype lacking ER/PR/HER2 expression is identified as triple-negative. A more recent gene 
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expression-based profiling provides five subtypes: luminal A, luminal B, HER2-positive, basal-like 
and normal-like [14-16].  
Luminal–like tumors are characterized by high expression of ER and PR and low rate of p53 
mutations. Generally, accumulation of ER in the nucleus of luminal-like tumor cells is considered as a 
driving factor. Indeed, anti-hormone therapies (anti-estrogen drugs) such as tamoxifen and aromatase 
inhibitors are effective against these types of tumors. As a result, diagnosis with hormone-positive 
breast cancer is regarded as good prognosis. The HER2-positive tumors are characterized by 
overexpression of the HER2 protein due to gene amplification and/or polysomy. HER2 is a 
constitutively-active receptor tyrosine kinase that can homodimerize or heterodimerize with family 
members to drive activation of the Ras-extracellular signal regulated kinase 1 and 2 (RAS(ERK1/2) 
and the phosphatidylinositol-3 kinase and Akt (PI3K-Akt) signaling pathways that are known to 
promote cancer cell growth and survival. Targeting the function of HER2 with specific drugs such as 
trastuzumab (herceptin) and the tyrosine kinase inhibitor lapatinib has shown efficacy against these 
types of tumors. Basel-like tumors constitutes a heterogeneous group of tumors. About 85% of basal-
like tumors are triple-negative and exhibit very high rates of p53 mutation and downregulation of 
breast cancer susceptibility gene 1 and 2 (BRCA-1 and BRCA-2) mutations. Another characteristic 
feature of basal-like tumors is dysregulation of multiple RTKs, including EGFR, c-MET, FGFR, and 
IGF-1R [17-23]. Normal breast-like are tumors cluster with normal breast samples in terms of gene 
expression profile.  
 
A3.2 Basal-like and triple-negative breast cancer  
Although the term triple-negative is not used in this classification, basal-like is often used as a 
surrogate since approximately 85% of basal-like tumors are triple-negative and vice versa [24-26]. 
Hereinafter, the term basal-like and triple-negative breast cancer (BTBC) which satisfies both 
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subgroups is used throughout this thesis. The basal-like and triple-negative breast cancer (BTBC) 
represents approximately 10-15% of all BCs, but it causes disproportionately high mortalities in 
women particularly in racial minorities and younger women of all races [27, 28]. One of the major 
factors to the poor clinical outcome is the lack of targeted therapy, which is further complicated by the 
multiplicity of dysregulated molecules that drive tumor growth and metastasis. Many reports show that 
the commonly dysregulated molecules in BTBC are receptor tyrosine kinases (RTKs) [17-23]. But, 
inhibition of individual RTKs did not lead to a substantial benefit to BTBC patients [29, 30]. It is 
therefore imperative to discover and target master-regulators of RTK signaling to overcome the 
difficulty posed by the multiplicity of dysregulated molecules. Recent reports show that the Src 
homology phosphotyrosyl phosphatase 2 (SHP2) is a master regulator of RTK signaling in BTBC. 




SHP2 is a non-receptor protein tyrosine phospatases that is encoded by the PTPN11 gene on 
chromosome 12.  SHP2 has two Src homology 2(SH2) domains in the N-terminal region and a protein 
tyrosine phosphatases (PTP) domain in the C-terminal region, and tyrosine phosphorylation sites in C-
terminal tail. The tyrosine phosphatase activity of SHP2 is regulated by an intermolecular 
conformational switch that closes and opens the PTP domain. In the resting state, SHP2 assumes a 
closed conformation mediated by interaction of the N-terminal SH2 domain with the PTP domain, 
leading to blockade of substrate binding to the active site. Interaction of the two SH2 domains with 
phosphotyrosine on interacting partner proteins induces an open conformation that allow substrate 
binding. Germline mutations that disrupt interaction between the N-SH2 and the PTP domain have 
been shown to lead to a constitutively active open conformation. SHP2 proteins with gain-of-function 
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mutations have been discovered in human disease and are regarded as causes for development of what 
is known as Noonan Syndrome characterized by facial abnormalities, cardiomyopathies, and increased 
incidence of hematopoietic malignancies. Increased activation of the Ras-extracellular signal regulated 
kinase 1 and 2 (Ras-ERK1/2) signaling pathway has been consistently found in patients with Noonan 
syndrome, suggesting that activation of SHP2 can lead to over-activation of this signaling pathway. 
Loss-of-function mutations of SHP2 have also been discovered in humans and are known to lead to 
development of LEOPARD syndrome. Children who harbor these two types of mutations have mental 
retardation, stunted growth, and death at a young age [31-34]. These findings suggested that SHP2 is 
needed for normal development in the heart, lungs, breast, and testis [35] and knockouts of SHP2 in 
mice is embryonic lethal.  In addition to mutational activation, increased tyrosine phosphorylation in a 
cell can also lead to over-activation of SHP2. For instance, overexpression of  a virulence factor 
cytotoxin-associated gene A(CagA) by Helicobacter pylori in gastric infection leads to over-activation 
of SHP2 which is cinsidered to be the caus of cancer development [36]. Src family tyrosine kinases 
have been shown to phosphorylate CagA which in turn interacts with the SH2 domains of SHP2 and 
activates its enzyme function by inducing an open conformation.  
The uniqueness of SHP2 is that its PTPase activity promotes rather than inhibits tyrosine kinase 
signaling [20, 37-39]. For instance, many receptor tyrosine kinase (RTK) known to date require SHP2 
to effectively activate the Ras-ERK1/2 and the phosphatidylinositol-3 kinase -Akt (PI3K-Akt) 
signaling pathways [17, 19-21, 23, 40-45]. But, the mechanism of SHP2 in mediating RTK signaling 
is poorly understood. The most daunting problem in understanding the mechanism of SHP2 is the 
elusiveness of biological substrates.  Only a handful publications have attempted to explain the 
mechanism of action. In EGFR and HER2 signaling, SHP2 mediates sustained Ras activation by 
blocking the Ras GTPase activating protein (RasGAP) for accessing Ras  at the plasma membrane 
through dephosphorylation of RasGAP docking sites on both receptor molecules  [41, 46]. In case of 
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FAK, SHP2 acts on pTyr397 to promote turnover of focal adhesions during cell migration [47] and in 
case of α-catenin SHP2 disrupts its interaction with β-catenin to increase its cytoplasmic pool [19]. 
Other reports show that SHP2 also promotes Src activation by blocking recruitment of the inhibitory 
C-terminal Src kinase (Csk) to the plasma membrane [44]. 
Because RTK overexpression in cancer including BC is commonplace and because SHP2 is a 
requisite downstream signal transducer, its state of expression was explored in cancer. SHP2 was first 
reported to be overexpressed in BC both in HER2-positrive and HER2-negative invasive ductal 
carcinomas by our laboratory [48] which was followed few years later by another group [49]. Since 
then, our laboratory has shown in multiple publications that SHP2 plays a fundamental role in BC. 
First, it was demonstrated that inhibition of SHP2 in both HER2-positive and basal-like and triple-
negative breast cancer (BTBC) cell lines induces mesenchymal to epithelial transition (MET) [50]. 
Second, it was shown that SHP2 is essential for cell polarity and migration  [51] and extracellular 
matrix degradation and invasion [52] in BTBC cells. Very interestingly, inhibition of SHP2 in BTBC 
cells induces basal-to-luminal transition, expression of estrogen receptor alpha (ERα), dependency on 
estrogen signaling for growth, and sensitivity to anti-estrogen (tamoxifen) therapy.  And third, it was 
demonstrated recently that SHP2 is essential for cell proliferation, transformation, tumorigenic and 
metastatic property of BTBC cells [53]. However, the mechanism of SHP2 in promoting these 
phenotypes in breast cancer particularly in BTBC is not understood. In this thesis work, the role and 
mechanism of SHP2 in BTBC cell growth, transformation, and proto-oncogene expression, and 
signaling has been investigated.  
 
 
C. Results  
C.1 SHP2 is important for basal signaling and mesenchymal growth properties in BTBC cells  
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To determine the functional significance of SHP2 in BTBC, we silenced SHP2 expression in two 
BTBC cell lines, the MDA-MB231 and the MDA-MB468 cells, which harbor multiple genetic 
changes commonly discovered in BTBC [54, 55]. These include activating Ras mutation in the 
MDA-MB231, elevated EGFR expression and p53 mutation in both [54, 56], and PTEN homo-
deletion and EGFR gene amplification in the MDA-MB468 cells [54, 57]. In addition, both cell lines 
show elevated SHP2 expression [48]. The expression of SHP2 was silenced with two independent 
shRNAs that were previously shown to be specific and devoid of off-target effects [47, 58]. Cells 
expressing luciferase shRNA were used as controls in this study. As shown in Fig.1A, 
immunoblotting (IB) analysis of total cell lysates showed effectively silencing of SHP2 expression by 
both shRNA constructs (sh-1 and sh-2). Because SHP2 is an essential mediator of mitogenic and cell 
survival signaling, we determined basal levels of Akt and extracellular signal regulated kinase 1 and 2 
(ERK1/2) activation and found a profound inhibition in both cases as assessed by the state of 
phosphorylation (Fig.1B). These findings suggest that silencing SHP2 suppresses basal signaling in 
BTBC cells. 
Observation of parental, control and SHP2-silenced cells (sh-1 and sh-2) growing in 2D under a 
microscope showed major morphological differences. When compared to the parental and the 
controls cells which are mesenchymal, elongated, and interspersed, the SHP2-silenced cells had 
acquired a flattened epithelial morphology characteristic of luminal epithelial cells (Fig.1C and D). 
These findings suggest that SHP2 is essential for the maintenance of the mesenchymal phenotype in 
BTBC cells and its inhibition leads to acquisition of a normal-looking epithelial phenotype. 
 
 
C.2 SHP2 is essential for cell proliferation, anchorage-independent growth, and cancer stem cell 
phenotypes in BTBC cells 
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Based on the effect of SHP2 inhibition on basal signaling and the mesenchymal growth properties, it 
was reasoned that SHP2 might also be important for the transformation phenotypes of BTBC cells. 
First, the effect of SHP2 silencing on cell proliferation rate was determined by direct counting. Equal 
number of cells were seeded in 2D cultures and the effect of SHP2 silencing on proliferation rate was 
determined by counting cells as described in the materials and methods section. The results showed 
that inhibition of SHP2 suppresses cell proliferation. While the parental and control cells proliferated 
by approximately 10 fold over 3 days, the SHP2-silenced cell grew by only 3-4 fold in the same 
period of time Fig.2A and B). Thus, SHP2 is essential for BTBC cell proliferation.  
Next, the effect of SHP2 silencing on anchorage-independent growth was determined. Equal 
number of parental, control and SHP2-silenced cells (sh-1 and sh-2) were seeded in soft agar and 
growth of colonies was monitor by microscopic examination. While the parental and the control cells 
formed larger and numerous colonies, the SHP2-silenced cells formed smaller and fewer ones 
(Fig.2C). Counting colony number per 4 objective showed approximately 22 larger colonies in the 
parental and control cells, but only 2-4 smaller colonies in the SHP2-silenced cells (Fig.2D). These 
findings suggested that SHP2 is essential for anchorage-independent growth in BTBC cells.  
The inability of the SHP2-silenced cells to grow in soft agar indicated a role for SHP2 in cancer 
stem cell (CSC) biology. To verify this point, the ability of cells to grow in suspension culture, in the 
so called mammosphere formation assay, was determined. In this assay, cells with stem-like 
properties only can survive and form mammospheres (also known as tumorisphere) [59, 60]. Whereas 
mammosphere-forming efficiency in the parental and the control cells was increased on successive 
passaging from primary to secondary cultures, it was exhausted in the SHP2-silenced cells (Fig.2E 
and G). To complement the mammosphere formation data, the effect of SHP2 on aldehyde 
dehydrogenase 1 (ALDH1) activity, another property of CSCs [61], was determined. To accomplish 
this task, the Millipore ALDEFLUOR assay kit was utilized. While the control MDA-MB231 cells 
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had 4.97% ALDH1-high cells, the corresponding SHP2-silenced cells had only 0.23%, a more than 
20-fold reduction (Fig.2F)). Similar results were obtained with the MDA-MB468 cells except that the 
proportion of CSCs in this cell line was higher relatively (Fig.2G ). Therefore, SHP2 is important for 
the maintenance of CSC phenotypes in BTBC cells.  
 
 
C.3 SHP2 is essential for expression and signaling by multiple RTKs in BTBC cells   
The low level of basal Akt and ERK1/2 activation was indicative of SHP2 regulating signaling by 
multiple receptor tyrosine kinases (RTKs) that are known to be dysregulated in BTBC. To test this 
possibility, the effect of SHP2 silencing on signaling by three RTKs, namely EGFR, FGFR1 and c-
MET, which are commonly dysregulated in BTBC, was studied in a time-course fashion. Control and 
SHP2-silenced (sh-2) cells were serum starved overnight and then stimulated with 20 ng/ml EGF, FGF 
or HGF for varying time points, ranging from 10 minutes to 4 hours, and lysates prepared from them 
were analyzed for Akt and ERK1/2 by immunoblotting with antibodies that recognized the activated 
forms. The results showed that Akt and ERK1/2 activation induced by the respective ligands were 
suboptimal and short-lived in the SHP2-silenced cells, but robust and sustained in the controls 
(Fig.3A-F). Hence, SHP2 is essential for dysregulated signaling by multiple RTKs in BTBC cells.  
Since receptor downregulation following ligand activation is a major process in terminating RTK 
signaling, it was reasoned that the rapid decay in signaling in the SHP2-silenced cells might be related 
to effect on this process. To test this possibility, the same total cell lysates were analyzed for EGFR. 
The results showed that the level of EGFR in the SHP2-silenced cells was very low in the first place 
and rapidly degraded upon EGF stimulation (Fig.3G and H). To substantiate these findings, total cell 
lysates from the parental, the control, and the two SHP2 shRNA cells were analyzed for basal levels of 
the three RTKs. The results showed a 6-8 fold reduction in EGFR, FGFR, and c-MET levels the 
11 
 
SHP2-silenced cells (Fig.3I). These findings confirmed that overexpression of the three RTKs that are 
commonly implicated in BTBC tumorigenesis is SHP2 dependent. 
 
C.4 SHP2 regulates the expression of β-catenin and its transcriptional targets in BTBC cells 
Based on previous reports that showed differential regulation of the Wnt/β-catenin signaling pathway 
in BTBC [62, 63] and the reported positive role of SHP2 in this signaling pathway [19, 64], it was 
reasoned that SHP2 may regulated Wnt/β-catenin signaling. This possibility is further supported by the 
drastic effect of SHP2 inhibition on cell proliferation and transformation which suggest the 
involvement of multiple signaling pathways. For this, the effect of SHP2 inhibition on the Wnt/β-
catenin pathway was studied. Because β-catenin stability is at the core of its signaling mechanism [65], 
the impact of SHP2 inhibition on total β-catenin protein level was studied first. The results showed a 
drastic reduction in β-catenin protein level in the SHP2-silenced cells (Fig.4A). Band density 
measurements further showed the presence of 8-10 fold β-catenin reduction in the SHP2-silenced cells 
(Fig.4B). As an indirect measure, we also determined the expression of two β-catenin target genes, 
cyclin D1 and c-Myc [66], under the same conditions. In agreement with the β-catenin level, cyclin D1 
and c-Myc were significantly reduced in the SHP2-silenced cells (Fig.4A). These results show that 
SHP2 is required for β-catenin stability and expression of target genes in BTBC cells, which in turn 
suggest that one of the mechanisms by which SHP2 promotes BTBC is by promoting Wnt/β-catenin 
signaling. 
The low level of total β-catenin and its transcriptional targets in the SHP2-silenced cells was an 
indication for a low cytoplasmic and nuclear β-catenin pool. To verify this point, cytoplasmic and 
nuclear protein extracts were analyzed for β-catenin by immunoblotting experiments. While the 
controls had higher cytoplasmic and nuclear β-catenin, the SHP2-silenced cells had very low 
cytoplasmic and undetectable nuclear β-catenin (Fig.4C). Reprobing for poly-ADP ribose polymerase 
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(PARP) and β-actin as nuclear and cytoplasmic markers, respectively, confirmed the integrity of the 
fractionation. To clarify this point further, β-catenin immunofluorescence (IF) studies were conducted. 
Consistent with the immunoblotting data, intense cytoplasmic and nuclear β-catenin staining was 
observed in the controls. On the other hand, the β-catenin signal in the SHP2-silenced cells was 
relatively low and mainly present at the plasma membrane (Fig.4D and E). These results confirm that 
SHP2 is required for cytoplasmic stability and nuclear localization of β-catenin in BTBC cells.  
To determine whether the effect of SHP2 is at protein or mRNA level, time course proteasome 
inhibition with Mg-132 that included shorter and longer time points were conducted. As shown in 
Fig.4F and G, β-catenin was restored within 3 hours in the SHP2-silenced cells. These findings are 
consistent with SHP2 promoting β-catenin stability by countering proteasomal degradation. Because 
regulation at a transcriptional level could not be ruled out, the effect of SHP2 silencing on β-catenin 
mRNA levels was determined by quantitative real-time PCR (qRT-PCR). The results showed no 
significant difference between the control and SHP2-silenced cells (Fig.4H), confirming that the effect 
of SHP2 is at a protein level. 
C.5 β-Catenin is essential for the growth and transformation of BTBC cells 
After demonstrating that SHP2 mediates β-catenin stability, it was logical to show whether or not 
β-catenin has any biological significance in BTBC cells. To address this point, the expression of β-
catenin was silenced in the MDA-MB231 and MDA-MB468 cells using two independent shRNA 
constructs, βsh1 and βsh2 (Fig.5A). In the same preparations, the levels of cyclin D1 and c-Myc, the β-
catenin transcriptional target genes, were determined. The results showed a substantial decrease in 
both proteins (Fig.5A).  
To test the biological significance of β-catenin in BTBC cells, the effect of silencing on cell 
proliferation was determined by direct counting. The results showed an approximately 50% drop in 
cell proliferation rate (Fig.5B), suggesting that β-catenin is important for the growth of BTBC cells. 
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Next, the effect of β-catenin silencing on cell transformation was determined by anchorage-
independent growth in soft agar. Silencing β-catenin suppressed colony formation in terms of size and 
number (Fig.5C). Counting colony number showed formation of 22-25 colonies by the parental and 
the control cells, but only 7 - 9 colonies by the β-catenin-silenced cells per field under the 4 objective 
(Fig.5D). Hence, silencing β-catenin in BTBC cells suppresses proliferation and transformation. 
 
C.6 β-Catenin is directly involved in the transcription of EGFR 
Because EGFR was previously suggested to be a direct target of β-catenin transcriptional activity 
[67] and because SHP2 is essential for β-catenin stability, it was reasoned that the positive role of 
SHP2 on EGFR mRNA expression in BTBC cells might be through its effect on β-catenin. To verify 
this point, the effect of β-catenin silencing on EGFR protein levels was determined by IB. The results 
showed a profound reduction (Fig.5E), reminiscing the levels found in the SHP2-silenced cells. To see 
if SHP2 might also be a target of β-catenin, its protein level was also determined. Similar to RGFR, 
the protein level of SHP2 also was downregulated drastically (Fig.5E). To confirm that the effect of β-
catenin silencing on EGFR and SHP2 was at a transcriptional level, the respective mRNAs were 
analyzed by qRT-PCR. The results showed an approximately 8-10 fold reduction in EGFR and SHP2 
mRNA levels in the β-catenin-silenced cells (Fig.5F). These findings suggest that β-catenin is essential 
for EGFR and SHP2 transcription. 
.   
D. Discussion 
Overexpression and Gene amplification of RTKs are a major mechanism for tumor growth 
and development in many forms of cancers[21, 33, 68].  EGFR and HER2 are overexpressed and gene 
amplified respectfully in some forms of BC and shown to be a driving factor leading to 
tumorigenesis[69-71].  SHP2 has been shown to be a positive mediator of both EGFR and HER2 in 
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HER2 positive breast cancer and to promote down signaling between both RTKs.  Many studies have 
been conducted to understand what causes such heterogeneity in BTBC that leads to dysregulation of 
multiple RTKs, a mutation in Ras, and dysregulated Wnt/beta-catenin signaling[72-74].  We are the 
first to show that silencing SHP2 in BTBC lead to a loss a tumor phenotype and SHP2 promotes 
signaling and expression of multiply RTKs and stabilizing β-catenin protein 
Two BTBC cells MDA-MB 231 and MDA-468 cell lines that are known to overexpresses 
EGFR[54, 56] were used in this study. Logical these cells would be the best to see the effect of SHP2 
silencing in BTBCs were SHP2 has been reported to be a positive mediator of EGFR signaling in 
HER2 positive breast cancer.  Silencing of SHP2 with two previously reported shRNA in both cell 
lines led to losing of a mesenchymal phenotype and reduced a normal epithelial phenotype. There was 
also a loss of basal signaling in these SHP2 silenced BTBC cells to MAP kinase and PI3K/AKT 
pathways for survival and growth.  Anchor independent growth of silenced SHP2 BTBC compared to 
control cell lines had a reduction in growth and overall colony size and number. Our data indicates that 
SHP2 needed to BTBC transformation phenotype which could be mediated by signaling to kinase and 
PI3K/AKT pathways.   
The effect of SHP2 silencing in BTBC on cell proliferation and transformation was very 
dramatic compared to parental and control cell lines in both MDA-MB231 and MDA-MB468.  This 
data aligns with the loss of basal signaling from AKT and ERK 1/2 , pathways that regulate growth 
and survival in BTBCs. CSC phenotype was also lost with the silencing of SHP2 in both MDA-
MB231 and MDA-MB 468 as shown form the mammosphere assay, where during the second passage 
the mammospheres formed were lost only in SHP2 silenced MDA-MB231 and MDA-MB468. This 
was confirmed by cell sorting for the ALDH1 which is a marker for stem cells. Indeed the population 
of ALDH1 high cells in the mammospheres was dramatically reduced in SHP2 silenced cells 
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compared to control cell lines, showing that SHP2 is regulating BTBC phenotype that has CSC 
properties that allow for growth in a 3D matrix.   
With multiple RTK being dysregulated in BTBCs and with the observation that basal 
signaling was lower for Akt and ERK 1/2 SHP2 could have a role is signaling for other RTKs in 
BTBCs.  This was indeed the case as shown with a loss of basal signaling form Akt and ERK 1/2 from 
FGF and HGF.  Along with all three RTKs protein level being reduced in SHP2 silenced MDA-
MB231 and MDA-MB468 compared to control cell lines, SHP2 must play a protective role in the 
protein stability of these RTKs. As shown in figure 2G and 2H SHP2 was protective for EGFR 
degradation by EGF stimulation as seen with control cells have little loss of EGFR protein compared 
to SHP2 silenced cells when have a massive reduction in EGFR protein levels at 10 minutes of EGF 
stimulation  in both MDA-MB231 and MDA-MB468.  This data shows that SHP2 is essential for 
activation of Akt and ERK 1/2  form multiple RTK and that SHP2 has a role in protein stability for 
each of these dysregulated RTKs in BTBCs.  
Wnt/Beta-catenin signaling has been shown to be dysregulated in BTBC, with 
overexpression of Wnt ligands[62, 75, 76].  A few studies have looked the functional role of β-catenin 
in BTBC with silencing β-catenin. β-catenin protein levels were also lower in SHP2 silenced cell lines. 
We wanted to see if β-catenin transcriptional targets were lower in SHP2 silenced MDA-MB231 and 
MDA-MB468 cells. The amount of protein for cyclin D1 and Myc were lower as expected, suggesting 
that ether the loss of  β-catenin protein levels  cause the loss of these transcriptional targets or that  β-
catenin was unable to translocate to the nucleus. With nuclear and cytoplasmic fraction studies, we 
showed that β-catenin was translocating in the nucleus only in control BTBCs and was only 
cytoplasmic in SHP2 silenced cells. Ifs for β-catenin  in SHP2 silenced cells and control MDA-MB231 
and MDA-MB468 show that β-catenin was manly at the plasma membrane in SHP2 silenced cells and 
control cells had both nuclear and cytoplasmic β-catenin. This   data  suggesting that SHP2 might be 
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promoting the translocation of β-catenin, where SHP2 is overexpressed in BTBC.  With MG132 
treatment of MDA-MB231 and MDA-MB468 SHP2 silenced cells and control cells , protein level of 
β-catenin were able to come back to the level of control protein level after 6 hours of treatment along 
with no statistically difference in the amount of β-catenin mRNA in SHP2 silenced and control 
BTBCs. This would suggest that SHP2 also promotes the half of β-catenin protein levels, and this 
could be the reason for the loss of translocation to the nucleus in SHP2 silenced BTBCs . 
The effect of β-catenin silencing in BTBCs showed similar results with the protein levels of β-
catenin transcriptional target genes as in SHP2 silenced BTBCs, with both cyclin D1 and Myc.  
However with the rate of cellular proliferation and tumorigenesis in β-catenin silenced cells was not a 
dramatic as with SHP2 silencing as shown with growth rates and anchorage-independent growth.  
With protein levels of EGFR also being lowered in  β-catenin silenced in BTBCs and SHP2 silenced 
BTBC could β-catenin be transcribing EGFR in BTBCs. As shown with RT-PCR ,β-catenin silenced  
BTBCs, had level of EGFR mRNA corresponded with EGFR  protein levels in β-catenin silenced  
BTBCs compare control cell lines. The importance of SHP2 for transformation in BTBCs was shown 
with EGFR mRNA expression was reduced in both SHP2 silenced and β-catenin silenced BTBCs and 
β-catenin mRNA expression was not affected by SHP2 silencing, suggesting that SHP2 is promoting 
transcription of EGFR by β-catenin protein stability. 
 More work is needed to understand what mechanism by which SHP2 plays in stabilizing β-catenin 
protein levels in BTBCs. Functional assays along with Chromatin immunoprecipitation could be done 
to show that  β-catenin is a transcription factor  EGFR in BTBCs . There is also the need to test if  
other RTKs such as FGFR and c-Met  are under the same regulation as EGFR in BTBCs.  In vivo 
studies are also needed to show that is novel feed-forward loop between EGFR/RTKs and Wnt/ β-
catenin is functional and plays a major role in transformation in BTBCs.  The data presented here 
shows a need to develop SHP2 inhibitors to the treatment of BTBCs. SHP2  seems to be a master 
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regulator of signaling in BTBCs that we have shown to promotes that protein stability and expression 
of targets that are used today in clinics to treat cancer.   
 
 
E Material and Methods   
E.1 Cells, cell culture and reagents 
The MDA-MB231 and the MDA-MB468 breast cancer cell lines and the MCF-10A normal breast 
epithelial cell line were purchased from American Type Culture Collection ( ATCC). All cells were 
cultured Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum at 37
0
C and 
5% carbon dioxide.  Antibodies that were used in this study anti-EGFR (610017), anti-SHP2 (610822) 
and PARP (611038) from BD Biosciences, anti-β-catenin ( Sc-7199 and SC-37684), anti-cyclin D1 
(SC-246), anti-pan-ERK2 (SC-81457), HSP 90 (SC-13119) formed Santa Cruz Biotechnology. The 
anti-β-actin (A5441) from Sigma-Aldrich, and anti-phospho-ERK ½ (9101S), anti-phospho-AKT 
(9271S) from Cell Signaling. Secondary antibodies conjugated to horseradish peroxidase anti-mouse, 
anti-rabbit and, anti-rat were from Jackson Immuno-Research Laboratories.  
 
E.2 Silencing SHP2, and β-catenin 
Silencing of SHP2 in MDA-MB231 and MDA-MB468 was described by our lab previously 
with two independent shRNA to show no off-target effects.  The silencing β-catenin in MDA-MB231 
and MDA-MB468, shRNA constructs (SHCLNG-NM_001904CTRCN0000314991 and 
TRCN0000314921) from Sigma were used. 293T cells were transfected with the shRNA constructs 
and supporting plasmids with FuGene ( Roche) transfection reagent, supernatants containing viral 
particles were collected 48 hours after transfection, and viral particles were used to infect target cells. 
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3 μg/mL of polybrene was added to increases the transfection efficiency. 1μg/mL of puromycin was 
added after 48 hours for the selection of transfected cells.  
 
E.3 Cell lysates, Immunoblotting, and cytoplasmic-nuclear fraction analyzes 
Total cell lysates were prepared in cell lysis buffer containing 20mM Tris-HCl, pH 7.2, 150 mM NaCl, 
50mM NaF, 1mM EDTA, 10% triton-X-100, 1mM sodium orthovanadate and protease inhibitor 
cocktail. Total cell lysates were centrifuged at 12,000 rpm for 10 minutes to clean lysates.  
Cytoplasmic and nuclear fraction were prepared as described previously with medication to 
cytoplasmic isolation buffer; we used cell lysis buffer in a 1:10 dilution from working concentration. 
Polyacrylamide gel electrophoresis was used to separate proteins and transfer to a nitrocellulose 
membrane and blocked with 3% bovine serum albumin. Membranes were incubated with primary 
antibodies overnight at 4
0
C; the fallowing day membranes were washed 3 times for 10 minutes with 
Tris-buffered saline with 0.1% Tween-20 (TBST). Secondary antibodies were incubated for 1 hour at 
room temperature and washed 3 times for 10 minutes with TBST.  For detection of Immunoblotting, 
the chemiluminescence kit, Western Lighting kit was used  
 
E.4 Cell proliferation rate 
Cellular proliferation was determined by counting cells from microscopic pictures chosen randomly. 
Cells were seeded in 100mm culture dishes, with 10 random pictures were taken with a 4x objective 
immediately after attachment, and every 24 hours up to 3 days using an Olympus IX71 microscope 
with attached CCD and Microsuite Basic Edition software.  The growth rate was determined by 
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driving the average number of cells at each time point to the initial time point (number of the cell after 
attachment).  
 
E.5 Proteasome inhibition and EGF, FGF and HGF stimulation  
Cells lines were allowed to grow near confluence and were serum starved overnight. The fallowing 
day cells were treated with MG-132 a proteasome inhibitor or stimulated with 20 ng/mL of EGF, FGF 
or HGF for 6 hours.  Cells were then harvested after 6 hours for downstream application for analysis in 
Immunoblotting or chromatin immunoprecipitation. 
 
E.6 Anchorage-independent growth assay and Mammosphere formation assay 
Anchorage-independent growth was used to determine cell transformation in soft agar as described 
previously.  The basement layer was formed by covering a 6 cm cell culture plates with 0.5% agar in 
growth medium and solidify by incubation at room temperature for 15 minutes aseptically. 
Approximately 10
5
 cells were then suspended in 2 mL of a mixture of growth medium and warm agar 
at a concentration of 0.3% and immediately poured onto the basement agar layer aseptically.  Once fed 
layer solidifies, the plates were transferred to an incubator and maintained at 37
o
C and 5% carbon 
dioxide for 15 days and monitored for colony formation.  The cells were fed with a mixture of growth 
medium and 0.3% agar twice, and feeding after that was with DMEM supplemented with 10% fetal 
bovine serum.  Colony formation was monitored by visualization using an Olympus IX71 microscope 
with attached CCD and Microsuite Basic Edition software.  Primary mammospheres were generated 
form bulk culterd cells and seeding ultra-low attachment plates, with 20,000 cells/ml in 
mammospheres media and allowed to grown to form mammospheres and was  monitored by 
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visualization using an Olympus IX71 microscope with attached CCD and Microsuite Basic Edition 
software. For passage of cells, spheres were collected and centrifuged gently and incubated for 3-5 
minutes in 0.125% trypisn and cell cluster disrupted by pipetting throught a 200 µl pipet tip. 
Microscope examination was done to see single cell suspension. For secondary mammnosphere 
formation singles cell suspensions from primary mammospheres were plated at 1,000 cells/cm
2  
 in 
mammospheres media on ultra-low attachment plates and was monitored by visualization using an 
Olympus IX71 microscope with attached CCD and Microsuite Basic Edition software . 
E.7 ALDH activity  
 The Aldefluor assay was used to identify and isolate stem-like cells form secondary mammospheres 
from SHP2 silenced cells and control cell lines. The assay was performed according to the 
manufacture’s instructions, and the ALDH-positive/hi population identified by comparing flow 
profiles form cells incubated with and without an ALDH inhibitor. Cell sorting was performed at the 
WVU Flow Cytometry core.   
E. 8 Immnofluorescence microsopy. 
 Cells were grown on a microscopic slide cover slip, cultures were fixed with 4% paraformaldehyde 
for 20 min, washed 3 times with phosphate-buffered saline (PBS), permeabilized with 0.2% Triton-X-
100 in PBS for 30 min, and blocked with 3% bovine serum albumin in PBS for 1 h. The samples were 
then stained with primary antibodies at 4 °C overnight, washed 3 times with phosphate-buffered saline 
containing 0.2% Triton-X-100, and incubated with fluorescent-labeled secondary antibodies for 1 h at 
room temperature. After washing three times, the chambers were removed, and slides were covered 
with appropriate size coverslips and sealed. Finally, slides were inverted and scanned with laser 






E.9 RNA isolation, cDNA synthesis, and RT-qPCR  
To determine mRNA expression in cells lines, SHP2 silenced, β-catenin silenced and control cell lines 
had total RNA isolated using TRizol reagent for Life Technologies following the manufacturer 
instructions.  The amount of RNA from each cell line was then quantified using Nano drop from 
BioRad, with 2 µG of RNA from each cell line used for cDNA synthesis by using the iScript Reverse 
Transcription Supermix For RT-qPCR from BioRad following the manufacturer instructions.  cDNA 
from each cell line was then employed in RT-qPCR, primers for EGFR and β-catenin Primer time 
primer were purchased from Integrated DNA Technologies. EGFR mRNA expression a determined by 
using the iQ SYBR Green Supermix from BioRad and β-catenin mRNA expression by TaqMan Gene 
Expression Master Mix from Applied Biosystems, both RT-qPCR reaction were run using the iCycler 
iQ from BioRad.  Data analysis was done by following the iCycler iQ instructions. Relative transcript 
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D.1 Figure 1.  Silencing of SHP2 in BTBC leads to reduction is transformation and basal 
signaling  
A.  Western blot of two shRNA targeted for SHP2, empty viral control, and parental cells of MDA-
MB231 and MDA-MB468, anti- β-actin immunoblot used as loading control. B. Western blot of basal 
P        C    sh-1   sh-2
MDA-MB 231 MDA-MB 468
SHP2
Β-actin
A) Silencing SHP2 expression







B) Silencing SHP2 inhibits basal signaling
Figure 1A and B
P       C     sh-1   sh-2
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MAP kinase and PI3K/AKT pathway of silenced SHP2, empty viral control, and parental cells of 
MDA-MB231 and MDA-MB468. Ant-phospho-ERK1/2 and Anti-phospho-Akt blot used for 
activation of pathways,  anti-pan-ERK2 and anti-pan-AKT blots used as loading controls C.  SHP2 
silenced MDA-MB231 and empty viral control MDA-MB231 and Parental MDA-MD231 cells grown 
to 90% confluency, observation of morphology under 4 x objective. D.  SHP2 silenced MDA-MB468 
and empty viral control MDA-MB468 and Parental MDA-MB468 cells grown to 90% confluency, 
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C) Effect on colony formation
Figure 2C
 
Figure 2A and B
A) Effect on MDA-MB231 growth
B) Effect on MDA-MB468 growth
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 D.2 Figuer2) Effect of SHP2 silencing on cell proliferation,  transformation and CSC population 
in  BTBCs  A.  Silenced SHP2 MDA-MB231 and empty viral control MDA-MB231 and parental 
MDA-MB231 were grown for 96 hours in DMEM and number of the cells were counted every 24 
hours after the initial count to see the rate of cellular proliferation B. Silenced SHP2 MDA-MB468 
and empty viral control MDA-MB468 and parental MDA-M B468 were grown for 96 hours in DMEM 
and number of the cells were counted every 24 hours after the initial count to see the rate of cellular 
proliferation  C.  Anchorage-independent growth assay of silenced SHP2, silenced EGFR and parental 
cell lines of MDA-MB231 and MDA-MB468. Images were taken under 10 x objective after 15 days; 
D. Bar graph shows quantification of colonies formed from each cell line MDA-MB231 and MDA-
MB468.  E, G Mammosphere formation of MDA-MB231 and MDA-MD468 respectfully of  SHP2 
silenced, empty viral control and parental cells. Primary mammospheres in first column and secondary 
passage mammospheres  second column. F, H Cells sorting of secondary passage mammospheres of 
MDA-MB231 and MDA-MB468 respectfully for ALDH1 high population of cells in control and 
SHP2 silenced mammospheres.     
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E) Effect of SHP2 on HGF signaling, MDA-MB231 
F) Effect of SHP2 on HGF signaling, MDA-MB468 
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I) Effect of SHP2 on RTK expression
  
D.3 Figure 3. Silencing of SHP2 leads to a loss of siganling and  expression  of mutplitpal RTKs 
in BTBCs  A, B,   MDA-MB231 and MDA-MB468 respectfully of SHP2 silenced sh-2, empty viral 
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control were stimulated with 20 ng/ml of EGF for 4 hours.    C, D MDA-MB231 and MDA-MB468 
respectfully of SHP2 silenced sh-2, empty viral control were stimulated with 20 ng/ml of FGF for 4 
hours.   E, F MDA-MB231 and MDA-MD468 respectfully of SHP2 silenced sh-2, empty viral control 
were stimulated with 20 ng/ml of HGF for 4 hours. All Western blots from A-F were analyzed for  
Ant-phospho-ERK1/2 and Anti-phospho-Akt blot used for activation of pathways,  anti-pan-ERK2 
and anti-pan-AKT blots used as loading controls during times-course  stimulation from control and 
SHP2 silenced sh-2 cell lines. G,H  MDA-MB231 and MDA-MD468 respectfully of SHP2 silenced 
sh-2, empty viral control were stimulated with 20 ng/ml of EGF for 4 hours. Western blots were 
analyzed for anti-EGFR during the time-course stimulation, anti- β-actin immunoblot used as loading 
control.  Western Blot of  MDA-MB231 and MDA-MD468 SHP2 silenced sh-1 , sh-2, empty viral 
control and parental cell lines. bolts were analyzed for EGFR, FGR and C-MET with Anti-EGFR, 
anti-FGFR, anti-C-MET with , anti- β-actin immunoblot used as loading control. 
 
MDA-MB231 MDA-MB468
C        N  C    N




C) Subcellular levels of β–catenin
C        N  C    N










A) Effect of SHP2 on β-catenin















































B) Effect of SHP2 on β-catenin, band density
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 D.4 Figure 4.  SHP2 promotes mRNA expression of EGRF in BTBCs.  
A.  Western blot for β-catenin target genes from SHP2 silenced MDA-MB231 and MDA-MB468, 
empty viral vector control, and parental cell line, Western blots were analyzed for anti-cyclin D1, anti-
Myc ,  anti-SHP2 and β-catenin, anti- β-actin immunoblot used as loading control B. Bar graph shows 
quantification of band density cell line MDA-MB231 and MDA-MB468. C Cytoplasmic and nuclear 
isolation from, MDA-MB231 and  MDA-MB468 SHP2 silenced and control cell lines. Wester blot 
analyed for β-catenin in the nucleus or cytoplasm by anti- for β-catenin with anti-PARP and  anti- β-
actin as nuclear and cytoplasmic loading controls respectfully . D, E.β-catenin Immunoflurosecence of 
MDA-MB231 and MDA-MB468 respectfully of SHP2 silenced sh-2, empty viral control. Labeled 
anti-β-catenin was used to visualize the subcelluar location of  β-catenin in SHP2 silenced cells and 
control .   F. Proteasome inhibition treatment of SHP2 silenced sh-2 and control of  MDA-MB231 and  
MDA-MB468. Both cells were serum starved overnight and the addition of  MG-132 to inhibit the 
proteasome for 6 hours. Immunoblot for β-catenin to observe protein stability of β-catenin in SHP2 
silenced MDA-MB231 and MDA-MB468 G. Bar graph show shows quantification band density form 
F for each cell line MDA-MB231 and MDA-MB468.    H, Real-time qPCR for β-catenin  mRNA 
expression in SHP2 silenced  and parental MDA-MB231 and MDA-MB468.   
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D.5 Figure 5.  EGFR is a transcriptional target of β-catenin in BTBCs  
A) Silencing of β-catenin is MDA-MB231 and MDA-MB468, two independent shRNA for β-catenin, 
empty viral vector control, and parental cell lines, immunoblot of β-catenin , cyclin D1 and Myc with 
anti-β-catenin, anti-cyclin D1 and anti-Myc with immunoblot of anti-β-actin as a loading control. B .  
Silenced β-catenin MDA-MB231 and MDA-MB 468 with  empty viral control  and parental cell lines 
were grown for 96 hours in DMEM and number of the cells were counted every 24 hours after the 
initial count to see the rate of cellular proliferation. C.  Anchorage-independent growth assay form 
silenced β-catenin and silenced SHP2 MDA-MB231 and MDA-MB468.  Images were taken under 10 
x objective after 15 days D. Bar graph shows quantification of colonies formed from each cell line in 
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E.  Western Blot of   β-catenin silenced MDA-MB231 and MDA-MB 468 with empty viral control  
and parental cell lines. Blots were analyzed for EGFR and SHP2 with anti-EGFR and anti-SHP2 with , 
anti- β-actin immunoblot used as loading control. F. Real-time qPCR for EGFR mRNA expression in 
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